Literature DB >> 12690374

Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.

Nils K Mungan1, Thomas W Wilson, Ken K Nischal, Gideon Koren, Alex V Levin.   

Abstract

Brimonidine is a selective alpha-2 adrenergic agonist used to treat glaucoma. There have been several reports of central nervous system depression after its use in infants. We observed rapid-onset bradycardia and decreased blood pressure in addition to central nervous system depression in 2 infants who received concomitant topical brimonidine and beta-blockers.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12690374     DOI： 10.1067/mpa.2003.S1091853102420137

Source DB:  PubMed          Journal:  J AAPOS        ISSN： 1091-8531            Impact factor:   1.220


  5 in total

1.  In vivo assessment of aqueous humor dynamics upon chronic ocular hypertension and hypotensive drug treatment using gadolinium-enhanced MRI.

Authors:  Leon C Ho; Ian P Conner; Chi-Wai Do; Seong-Gi Kim; Ed X Wu; Gadi Wollstein; Joel S Schuman; Kevin C Chan
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-24       Impact factor: 4.799

Review 2.  Pharmacologic management of glaucoma in childhood.

Authors:  Will Moore; Ken K Nischal
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

3.  Safety of apraclonidine eye drops in diagnosis of Horner syndrome in an outpatient pediatric ophthalmology clinic.

Authors:  Amgad A Eldib; Preeti Patil; Ken K Nischal; Ellen R Mitchell; Jamila G Hiasat; Matthew S Pihlblad
Journal:  J AAPOS       Date:  2021-11-02       Impact factor: 1.220

4.  Respiratuvar depression after accidental nasal ingestion of brimonidine eye drops in infant.

Authors:  Ali Gunes; Hasan Balik; Servet Yel; Halil Kocamaz; Mehmet Bosnak
Journal:  Turk J Emerg Med       Date:  2016-02-22

Review 5.  Rare Diseases Leading to Childhood Glaucoma: Epidemiology, Pathophysiogenesis, and Management.

Authors:  Solmaz Abdolrahimzadeh; Valeria Fameli; Roberto Mollo; Maria Teresa Contestabile; Andrea Perdicchi; Santi Maria Recupero
Journal:  Biomed Res Int       Date:  2015-09-16       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.